CA2561728A1 - Compositions bioadhesives bifonctionelles destinees a l'implantologie orale - Google Patents
Compositions bioadhesives bifonctionelles destinees a l'implantologie orale Download PDFInfo
- Publication number
- CA2561728A1 CA2561728A1 CA002561728A CA2561728A CA2561728A1 CA 2561728 A1 CA2561728 A1 CA 2561728A1 CA 002561728 A CA002561728 A CA 002561728A CA 2561728 A CA2561728 A CA 2561728A CA 2561728 A1 CA2561728 A1 CA 2561728A1
- Authority
- CA
- Canada
- Prior art keywords
- solution
- similar
- polyoxyethylene sorbitan
- drug
- sorbitan monolaurate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000227 bioadhesive Substances 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title abstract description 26
- 230000001588 bifunctional effect Effects 0.000 title description 3
- 239000007943 implant Substances 0.000 claims abstract description 40
- 229940079593 drug Drugs 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 39
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 25
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 25
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 25
- 229940122361 Bisphosphonate Drugs 0.000 claims abstract description 24
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract description 24
- 230000011164 ossification Effects 0.000 claims abstract description 6
- 238000011065 in-situ storage Methods 0.000 claims abstract description 5
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229960002286 clodronic acid Drugs 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 3
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 3
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 3
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 3
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims description 3
- 229940062527 alendronate Drugs 0.000 claims description 3
- 229960004585 etidronic acid Drugs 0.000 claims description 3
- 229940015872 ibandronate Drugs 0.000 claims description 3
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims description 3
- 229950010733 neridronic acid Drugs 0.000 claims description 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 3
- 229940046231 pamidronate Drugs 0.000 claims description 3
- 229940089617 risedronate Drugs 0.000 claims description 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 3
- 229960004276 zoledronic acid Drugs 0.000 claims description 3
- 238000007596 consolidation process Methods 0.000 claims description 2
- 239000004053 dental implant Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000008468 bone growth Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000009471 action Effects 0.000 abstract description 12
- 230000002035 prolonged effect Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 31
- 238000009472 formulation Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 6
- 230000035587 bioadhesion Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 239000012049 topical pharmaceutical composition Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000707825 Argyrosomus regius Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 241000404883 Pisa Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000012835 hanging drop method Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000001966 tensiometry Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20040641 ITMI20040641A1 (it) | 2004-03-31 | 2004-03-31 | Composizioni bioadesive bifunzionali per implantologia orale |
| ITMI2004A000641 | 2004-03-31 | ||
| PCT/EP2005/051440 WO2005094784A2 (fr) | 2004-03-31 | 2005-03-30 | Compositions bioadhesives bifonctionelles destinees a l'implantologie orale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2561728A1 true CA2561728A1 (fr) | 2005-10-13 |
Family
ID=35064438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002561728A Abandoned CA2561728A1 (fr) | 2004-03-31 | 2005-03-30 | Compositions bioadhesives bifonctionelles destinees a l'implantologie orale |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1773291A2 (fr) |
| BR (1) | BRPI0508805A (fr) |
| CA (1) | CA2561728A1 (fr) |
| IT (1) | ITMI20040641A1 (fr) |
| WO (1) | WO2005094784A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2379485T3 (es) | 2005-10-27 | 2012-04-26 | Thommen Medical Ag | Implante dental y procedimiento para su fabricación |
| WO2007048263A2 (fr) * | 2005-10-27 | 2007-05-03 | Nexilis Ag | Implant et procede de fabrication |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5403829A (en) * | 1993-03-24 | 1995-04-04 | Leiras Oy | Use of bisphosphonates in endo-osteal bone surgery |
| US6572874B1 (en) * | 1998-05-15 | 2003-06-03 | Umd, Inc. | Vaginal delivery of bisphosphonates |
| AUPQ232599A0 (en) * | 1999-08-19 | 1999-09-09 | Royal Alexandra Hospital For Children, The | Drug for treating fractures |
-
2004
- 2004-03-31 IT ITMI20040641 patent/ITMI20040641A1/it unknown
-
2005
- 2005-03-30 EP EP05729467A patent/EP1773291A2/fr not_active Withdrawn
- 2005-03-30 WO PCT/EP2005/051440 patent/WO2005094784A2/fr not_active Application Discontinuation
- 2005-03-30 BR BRPI0508805-4A patent/BRPI0508805A/pt not_active IP Right Cessation
- 2005-03-30 CA CA002561728A patent/CA2561728A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0508805A (pt) | 2007-08-07 |
| WO2005094784A3 (fr) | 2006-05-11 |
| ITMI20040641A1 (it) | 2004-06-30 |
| EP1773291A2 (fr) | 2007-04-18 |
| WO2005094784A2 (fr) | 2005-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fazil et al. | Bisphosphonates: therapeutics potential and recent advances in drug delivery | |
| US8071574B2 (en) | Implant improving local bone formation | |
| JP6053083B2 (ja) | 徐放性薬剤キャリア組成物 | |
| Asafo-Adjei et al. | Advances in controlled drug delivery for treatment of osteoporosis | |
| EP3274003B1 (fr) | Substitut osseux céramique bi-phasique | |
| KR101883807B1 (ko) | 뼈 보이드 및 개방형 골절의 치료용 조성물 및 방법 | |
| Emanuel et al. | A lipid-and-polymer-based novel local drug delivery system—BonyPid™: From physicochemical aspects to therapy of bacterially infected bones | |
| NZ283430A (en) | Use of methanebisphosphonic acid derivatives for preventing prosthesis loosening and prosthesis migration | |
| Alenezi et al. | Osseointegration effects of local release of strontium ranelate from implant surfaces in rats | |
| WO1996039107A1 (fr) | Composition a base de ciment de bisphosphonate permettant d'eviter le relachement aseptique des protheses orthopediques | |
| ES2379485T3 (es) | Implante dental y procedimiento para su fabricación | |
| CN107072885B (zh) | 用于治疗种植体周围炎的方法 | |
| WO2014032099A1 (fr) | Composition et procédé pour la croissance osseuse | |
| WO2001010463A1 (fr) | Pates a liberation prolongee d'un promoteur de l'osteogenese | |
| JP2024037985A (ja) | 人工骨膜 | |
| Gallarate et al. | Osteomyelitis: focus on conventional treatments and innovative drug delivery systems | |
| WO2005069837A2 (fr) | Compositions non aqueuses pour traiter des defauts orthopediques et administrer des agents bioactifs | |
| CA2561728A1 (fr) | Compositions bioadhesives bifonctionelles destinees a l'implantologie orale | |
| EP3116555B1 (fr) | Combinaison agent actif-particule favorisant la régénération osseuse | |
| Manzano | Ceramics for drug delivery | |
| IT201800002841A1 (it) | Film biopolimerico per il rilascio localizzato di principi attivi | |
| Mendes | Effect of local delivery of HEBP and inorganic pyrophosphate on bone healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |